Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950299 · ClinicalTrials.gov registry record · Phase 2
Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT01950299 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 99 participants.
The verdict
NCT01950299, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.
Interventions
- DRUG Placebo
- DRUG Anakinra 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-07-01 |
| Est. Completion | 2018-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950299
The ClinicalTrials.gov registry entry for NCT01950299 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01950299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950299 about?
NCT01950299 is a clinical study titled "Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)". VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.
What is the current status of trial NCT01950299?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2014-07-01. Estimated completion is 2018-12-23.
What interventions are being tested in trial NCT01950299?
The interventions under investigation include: Placebo (DRUG), Anakinra 100 mg (DRUG).
Who is sponsoring clinical trial NCT01950299?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.